Development of method of quantitative determination of cardiazol substance with using highly efficient liquid chromatography

Authors

DOI:

https://doi.org/10.15587/2519-4852.2019.165763

Keywords:

Cardiazole, cardioprotective activity, analysis, method of quantitative determination, high performance liquid chromatography.

Abstract

The aim. Development of methods of quantitative determination of Cardiazol substance using high-performance liquid chromatography.

Materials and methods. The method of high-performance liquid chromato-graphy (HPLC) was to determine of quantitative determination of Cardiazol substance ([3-Allil-4-(41-methoxyphenyl)-3H-thiazole-2-ylidene]-(32-trifluoro-methylphenyl)amine hydrobromide) using Shimadzu Nexera X2 LC -30AD (Shimad-zu, Japan). The acetonitrile of the HPLC grade (Sigma-Aldrich GmbH, Switzerland) was used in the work and other chemicals and solvents were of analytical grade. The test substance was diluted in acetonitrile at a final concentration of 400 μg/ml.

Results and discussion. The method of quantitative determination of Cardiazol substance with the help of highly effective liquid chromatography is developed. The developed conditions of testing are selected experimentally. The following optimal conditions for the chromatographic distribution were found: column C8 (250 *4.6 mm; speed of the mobile phase 1 ml/min; thermostat temperature of the column 35 ° C; detecting wavelength 300 nm; holding time of the test compound is 13.9 min. Suitability of determination methods.

The following optimal conditions for chromatographic separation were revealed: a C8 column (250*4.6 mm, a mobile phase speed of 1 ml/min, a column thermostat temperature of 35 °C, a detection wavelength of 300 nm. Under the proposed conditions, the retention time of the tested component is 13.9 minutes. The performance of the column was determined for its main indicators, such as the theoretical number of plates (over 65000) and the coefficient of symmetry (about 1.00). The method of quantitative determination was tested in accordance with the recommendations of the Ukrainian and European Pharmacopoeia. The proposed method meets all requirements. The method has been tested for the effects of various factors such as flow rate, the composition of the mobile phase and the temperature of the column thermostat. It is established that the influence of these factors is insignificant and does not affect the results obtained by this method.

Conclusions. An analytical method for quantitative determination of Сardiazole substance with cardioprotective action has been developed on the basis of the high-performance liquid chromatography method. The conditions for chromatographic analysis (HPLC) were standardized. Requirements for the test "Checking the suitability of the chromatographic system" were established. The statistical processing of the results of the experiment shows that the relative uncertainty of the average result was within the permissible limits. The developed method for the determination of Сardiazole will be used for further study of substance as a component of various dosage forms

Author Biographies

Iryna Drapak, Danylo Halytsky Lviv National Medical University Pekarska str., 69, Lviv, Ukraine, 79010

PhD, Associate Professor

Department of General, Bioinorganic, Physical and Colloidal Chemistry

Borys Zimenkovsky, Danylo Halytsky Lviv National Medical University Pekarska str., 69, Lviv, Ukraine, 79010

Doctor of Pharmaceutical Sciences, Professor

Department of Pharmaceutical, Organic and Bioorganic Chemistry

Ivan Bezruk, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraina, 61002

Postgtaduate student

Department of Pharmaceutical Chemistry

Liudas Ivanauskas, Lithuanian University of Health Sciences A. Mickevičiaus g. 9, Kaunas, Lithuania, LT 44307

PhD, Professor

Department of Analytical and Toxicological Chemistry

Lina Perekhoda, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

Doctor of Pharmaceutical Sciences, Professor

Department of Medicinal Chemistry

Svitlana Harna, National University of Pharmacy Pushkinska str., 53, Kharkiv, Ukraine, 61002

Doctor of Pharmaceutical Sciences, Professor

Department of Quality, Standartization and Sertification of Drugs

References

  1. Kovalenko, V. M., Dolzhenko, M. M., Nesukai, Ye. H., Diachenko, Ya. S. (2016). Comparative characteristics of the cardiovascular disease prevention in Ukraine and Europe according to EUROASPIRE IV data: a hospital line. Arterial'naya gipertenziya, 1, 41–80.
  2. The top 10 causes of death. WHO. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
  3. Yeromina, H. O., Drapak, I. V., Perekhoda, L. O., Yaremenko, V. D., Demchenko, A. M. (2016). Synthesis of 2-(4-aryl(adamantyl)-2-phenyliminothiazol-3-yl)-ethanol derivatives and prediction of their biological activity. Der Pharma Chemica, 8 (3), 64–70.
  4. Perekhoda, L., Yeromina, H., Drapak, I., Kobzar, N., Smolskiy, O., Demchenko, N. (2017). The antioxidant properties of 1-[2-(R-phenylimino)-4-methyl-3-(3-[morpholine-4yl]propyl)-2,3-dihydro-1,3-thiazol-5-yl]ethane-1-one derivatives under conditions of artificial oxidative stress in vitro. Saudi Journal of Medical and Pharmaceutical Sciences, 3 (1), 55–59.
  5. Drapak, I., Perekhoda, L., Vynogradova, O., Protopopov, M., Suleiman, M., Sych, I., Kobzar, N., Kiz, O. (2018). The use of the docking studies with the purpose of searching potential cardioprotectors. Pharmacia, 2, 40–46.
  6. Perekhoda, L. O., Drapak, I. V., Suleiman, M. M., Sych, I. A., Yaremenko, V. D. (2017). Synthesis and in silico research of derivatives of 3-allyl-4-(R-phenyl)-N-(R1-phenyl)thiazole-2-imine. Der Pharma Chemica, 9 (13), 95–98.
  7. Herashchenko, I. V., Drapak, I. V., Demchenko, A. M., Perekhoda, L. O., Niektiehaiev, I. O. (2017). Pat. No. 122197 UA. Hidrobromid [3-alil-4-(41-metoksyfenil)-3N-tiazol-2-iliden]-(32-tryfluorometylfenil)aminu, shcho maie kardioprotektorni vlastyvosti. No. u201707267; declareted: 10.07.2017; published: 26.12.2017, Bul. No. 24.
  8. O' Sullivan, J., Blake, K., Berntgen, M., Salmonson, T., Welink, J. (2018). Overview of the European Medicines Agency's Development of Product-Specific Bioequivalence Guidelines. Clinical Pharmacology & Therapeutics, 104 (3), 539–545. doi: https://doi.org/10.1002/cpt.957
  9. Andrade, E. L., Bento, A. F., Cavalli, J., Oliveira, S. K., Schwanke, R. C., Siqueira, J. M. et. al. (2016). Non-clinical studies in the process of new drug development – Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Brazilian Journal of Medical and Biological Research, 49 (12). doi: https://doi.org/10.1590/1414-431x20165646
  10. Haleem, R. M., Salem, M. Y., Fatahallah, F. A., Abdelfattah, L. E. (2015). Quality in the pharmaceutical industry – A literature review. Saudi Pharmaceutical Journal, 23 (5), 463–469. doi: https://doi.org/10.1016/j.jsps.2013.11.004
  11. Baumann, M., Baxendale, I. R. (2015). The synthesis of active pharmaceutical ingredients (APIs) using continuous flow chemistry. Beilstein Journal of Organic Chemistry, 11, 1194–1219. doi: https://doi.org/10.3762/bjoc.11.134
  12. Yeromina, H. O., Yeromina, Z. H., Sych, I. A., Perekhoda, L. O. (2017). Rozrobka metodyky kilkisnoho vyznachennia substantsiyi hidrobromidu (3-etyl-4-fenil-3N-tiazol-2-iliden)- [4-(6,7,8,9-tetrahidro-5N-[1,2,4]tryazolo[4,3-a]azepin-3-yil)fenil]aminu. Upravlinnia yakistiu v farmatsiyi: mat. XI nauk.-prakt. konf. Kharkiv, 64.
  13. Shim, J.-S. K., Tolan, J. W., Fink, D. W. (1980). Fluorometric Determination of Thiazole-Containing Compounds. Journal of Pharmaceutical Sciences, 69 (3), 275–279. doi: https://doi.org/10.1002/jps.2600690308
  14. El-Walily, A. F. M., Gazy, A. A., Belal, S. F., Khamis, E. F. (2000). Quantitative determination of some thiazole cephalosporins through complexation with palladium (II) chloride. Journal of Pharmaceutical and Biomedical Analysis, 22 (2), 385–392. doi: https://doi.org/10.1016/s0731-7085(99)00281-2
  15. Nikolin, B., Imamović, B., Medanhodžić-Vuk, S., Sober, M. (2004). High performance liquid chromatography in pharmaceutical analyses. Bosnian Journal of Basic Medical Sciences, 4 (2), 5–9. doi: https://doi.org/10.17305/bjbms.2004.3405
  16. Pakhomov, V. P. (2003). Khromatohrafiya u khimiko-farmatsevtychnykh doslidzhenniakh. Khymyko-farmatsevtycheskyi zhurnal, 37 (8), 55–56.
  17. Derzhavna Farmakopeia Ukrainy. Vol. 1 (2015). Kharkiv: DP «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv», 1128.
  18. European Pharmacopoeia (2017). European Directorate for the Quality of Medicines & Health Care. Strasbourg.

Downloads

Published

2019-04-30

How to Cite

Drapak, I., Zimenkovsky, B., Bezruk, I., Ivanauskas, L., Perekhoda, L., & Harna, S. (2019). Development of method of quantitative determination of cardiazol substance with using highly efficient liquid chromatography. ScienceRise: Pharmaceutical Science, (2 (18), 33–38. https://doi.org/10.15587/2519-4852.2019.165763

Issue

No. 2 (18) (2019)

Section

Pharmaceutical Science

License

Copyright (c) 2019 Iryna Drapak, Borys Zimenkovsky, Ivan Bezruk, Liudas Ivanauskas, Lina Perekhoda, Svitlana Harna

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons Attribution 4.0 International License copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.

3. Authors have the right to store the final accepted version of the article in an institutional, thematic, or any other repository to ensure visibility and accessibility.